-+ 0.00%
-+ 0.00%
-+ 0.00%

FILANA THERAPEUTICS, - SUBJECTS ELIGIBLE FOR 48-WEEK EXTENSION STUDY AFTER DOUBLE-BLIND PHASE

Reuters·09/22/2026 12:02:51